Press Release
26 November 2026 08:00:00 CET

Vivesto reports positive Cantrixil results in canine cancer cell lines, supporting continued development for the treatment of cancer in dogs

Solna, Sweden, November 26, 2026 – Vivesto AB, an oncology-focused development company, today announces that Cantrixil has shown clear positive results in studies with different canine cancer cell lines. The results, together with previous positive pharmacokinetic and toxicology data in dogs, support continued development of Cantrixil for the treatment of cancer in dogs. The next step is to plan a clinical pilot study in dogs with cancer.

The new results from studies in different canine cancer cell lines complement the previous positive results from the company's exploratory PK/toxicology study in dogs, which showed that intravenously administered Cantrixil performs as intended in terms of blood concentration levels and half-life, while being well tolerated at all dose levels studied.

"The positive results are another important step in the development of Cantrixil in veterinary oncology. Together with the PK/tox data in dogs that we reported at the beginning of the summer, we now have a strengthened foundation for taking the program forward into clinical development. The next step is to plan a first pilot study in dogs with cancer," says Erik Kinnman, CEO of Vivesto.

Cantrixil is also being developed for the treatment of acute myeloid leukemia (AML) in humans and has previously been evaluated in a clinical development program in ovarian cancer. In November 2026, Cantrixil received Orphan Drug Designation in the U.S. in AML, which enables incentives during the development phase as well as market exclusivity upon approval. In light of Cantrixil's unique mechanism of action and promising safety profile, Vivesto decided in March 2026 to broaden the development of Cantrixil to also include cancer in dogs, in order to strengthen the company's veterinary oncology program.

For More Information:

Erik Kinnman, Chief Executive Officer
Phone: +46 018-50 54 40
E-mail: IR@vivesto.com

About Vivesto AB

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors. Vivesto's shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.

Attachments

Vivesto reports positive Cantrixil results in canine cancer cell lines, supporting continued development for the treatment of cancer in dogs